Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (610) Arrow Down
Filter Results: (610) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (610)
    • People  (4)
    • News  (110)
    • Research  (426)
    • Events  (3)
    • Multimedia  (4)
  • Faculty Publications  (259)

Show Results For

  • All HBS Web  (610)
    • People  (4)
    • News  (110)
    • Research  (426)
    • Events  (3)
    • Multimedia  (4)
  • Faculty Publications  (259)
← Page 13 of 610 Results →
  • 15 May 2007
  • First Look

First Look: May 15, 2007

Purchase this note: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=907412 HDFC (A) Harvard Business School Case 301-093 The top management team at India's leading home finance company must decide how to deal with the... View Details
Keywords: Martha Lagace
  • June 1998
  • Supplement

MBA Integrative Exercise: General Management, April 1998

By: Carin-Isabel Knoop
Drummond Paris, Regional Pharma Head, Asia/Pacific Novartis AG, discusses the company situation in Indonesia: joint ventures, budget, keeping track, and the prognosis for the future. View Details
Keywords: Business or Company Management; Joint Ventures; Forecasting and Prediction; Pharmaceutical Industry; Indonesia
Citation
Purchase
Related
Knoop, Carin-Isabel. "MBA Integrative Exercise: General Management, April 1998." Harvard Business School Video Supplement 898-503, June 1998.

    V. Kasturi Rangan

    Kash Rangan is the Malcolm P. McNair Professor of Marketing at the Harvard Business School. Formerly the chairman of the Marketing Department (1998-2002), he is now the co-chairman of the school's Social Enterprise Initiative. He has taught in a wide variety of MBA... View Details

    Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
    • April 2009
    • Case

    Merck: Managing Vioxx (A)

    By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
    This two-class case series allows students to stand in the shoes of CEO Ray Gilmartin during the unfolding stages of a reputational crisis. Merck's mission statement claims to "put patients first," but the company is widely criticized for putting profit before patient... View Details
    Keywords: Ethics; Crisis Management; Reputation; Decision Choices and Conditions; Customers; Business or Company Management; Cost vs Benefits; Corporate Accountability; Business and Shareholder Relations; Business and Stakeholder Relations; Customer Focus and Relationships; Pharmaceutical Industry
    Citation
    Educators
    Purchase
    Related
    Simons, Robert L., Kathryn Rosenberg, and Natalie Kindred. "Merck: Managing Vioxx (A)." Harvard Business School Case 109-080, April 2009.

      Ranjay Gulati

      Ranjay Gulati is the Paul R. Lawrence MBA Class of 1942 Professor of Business Administration and the former Unit Head of the Organizational Behavior Unit at Harvard Business School. His pathbreaking research, which focuses on unlocking organizational and unleashing... View Details

      Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
      • 21 Apr 2009
      • First Look

      First Look: April 21, 2009

        Working PapersHow Firms Respond to Being Rated (revised) Authors:Aaron K. Chatterji and Michael W. Toffel Abstract While many rating systems seek to help buyers overcome information asymmetries when making purchasing decisions, we investigate how these ratings also... View Details
      Keywords: Martha Lagace
      • June 2023 (Revised June 2023)
      • Supplement

      Roche: ESG and Access to Healthcare

      By: George Serafeim
      In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that had... View Details
      Keywords: ESG (Environmental, Social, Governance) Performance; Sustainable Finance; Growth Strategy And Execution; Sustainability Targets; Impact Evaluation; Healthcare Access; Healthcare Innovation; Healthcare Systems; Healthcare Operations; Finance; Strategy; Health Testing and Trials; Health Care and Treatment; Growth Management; Measurement and Metrics; Innovation Strategy; Corporate Social Responsibility and Impact; Health Industry; Pharmaceutical Industry; Switzerland; North America; Europe; Asia; Latin America; Africa
      Citation
      Purchase
      Related
      Serafeim, George. "Roche: Innovation and Access to Healthcare." Harvard Business School Multimedia/Video Supplement 123-713, June 2023. (Revised June 2023.)
      • December 2005 (Revised August 2006)
      • Case

      Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug

      By: Felix Oberholzer-Gee and Dennis A. Yao
      Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and... View Details
      Keywords: Health Care and Treatment; Strategic Planning; Competition; Patents; Innovation and Invention; Pharmaceutical Industry; Pharmaceutical Industry; United States
      Citation
      Educators
      Purchase
      Related
      Oberholzer-Gee, Felix, and Dennis A. Yao. "Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug." Harvard Business School Case 706-454, December 2005. (Revised August 2006.)
      • December 2019
      • Case

      The Business of Pain: Johnson & Johnson and the Promise of Opioids

      By: Erik Snowberg, Trevor Fetter and Amy W. Schulman
      This case is designed to provide an engrossing overview of stakeholder capitalism through a vigorous discussion of the conflicts that can arise when trying to serve multiple stakeholders. In 2007, Johnson & Johnson’s (J&J) subsidiary Janssen has to decide whether or... View Details
      Keywords: Opioids; Addiction; Stakeholder Capitalism; Business and Stakeholder Relations; Product Launch; Decision Making; Ethics; Social Issues; Pharmaceutical Industry
      Citation
      Educators
      Purchase
      Related
      Snowberg, Erik, Trevor Fetter, and Amy W. Schulman. "The Business of Pain: Johnson & Johnson and the Promise of Opioids." Harvard Business School Case 720-420, December 2019.

        Rosabeth M. Kanter

        Rosabeth Moss Kanter holds the Ernest L. Arbuckle Professorship at Harvard Business School, specializing in strategy, innovation, and leadership for change. Her strategic and practical insights guide leaders worldwide through teaching, writing, and direct... View Details

        Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
        • April 2023
        • Case

        Elliott Management: Capital Allocation in Biopharma

        By: Amitabh Chandra, Paul Clancy and Lauren Gunasti
        The case explores the intersection of capital allocation and shareholder activism in the biopharmaceutical industry. As many biopharma companies face looming patent expirations for key medicines, the case asks the question of whether investing in R&D and M&A is an... View Details
        Keywords: Finance; Strategy; Capital Allocation; Biopharmaceutical Industry; Shareholder Activism; Investment Activism; Resource Allocation; Research and Development; Business and Shareholder Relations; Corporate Strategy; Pharmaceutical Industry
        Citation
        Educators
        Purchase
        Related
        Chandra, Amitabh, Paul Clancy, and Lauren Gunasti. "Elliott Management: Capital Allocation in Biopharma." Harvard Business School Case 623-045, April 2023.

          Rohit Deshpande

          Rohit Deshpandé is a Baker Foundation Professor and Sebastian S. Kresge Professor of Marketing, Emeritus at Harvard Business School, where he has been teaching in the Advanced Management Program,... View Details

          Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
          • November 2006 (Revised May 2025)
          • Case

          Eli Lilly: Developing Cymbalta

          By: Elie Ofek and Ron Laufer
          Anticipating the expiration of its Prozac patent, Eli Lilly has to make tough decisions regarding the development of its next-generation antidepressant drug. In particular, the company needs to decide whether to first establish that once-a-day dosing for Cymbalta... View Details
          Keywords: Decision Choices and Conditions; Marketing Strategy; Product Launch; Product Development; Research and Development; Pharmaceutical Industry
          Citation
          Educators
          Purchase
          Related
          Ofek, Elie, and Ron Laufer. "Eli Lilly: Developing Cymbalta." Harvard Business School Case 507-044, November 2006. (Revised May 2025.)
          • December 2008 (Revised October 2013)
          • Case

          Amylin Pharmaceuticals: Diabetes and Beyond (A)

          By: Richard G. Hamermesh and Rachel Gordon
          Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of taking the company's signature drug, Symlin, to market. However, unforeseen regulatory challenges have put the approval process in jeopardy. At the same time, the company has a... View Details
          Keywords: Regulations; Drug Regulations; Symlin; Negotiation; Governing Rules, Regulations, and Reforms; Resource Allocation; Negotiation Deal; Product Development; Research and Development; Commercialization; Pharmaceutical Industry; United States
          Citation
          Educators
          Purchase
          Related
          Hamermesh, Richard G., and Rachel Gordon. "Amylin Pharmaceuticals: Diabetes and Beyond (A)." Harvard Business School Case 809-011, December 2008. (Revised October 2013.)

            William A. Sahlman

            William Sahlman is a Baker Foundation Professor of Business Administration at Harvard Business School.

            Mr. Sahlman received an A.B. degree in Economics from Princeton University (1972), an M.B.A. from Harvard University (1975), and a Ph.D. in Business... View Details

            Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
            • September 2010 (Revised July 2013)
            • Case

            Alnylam Pharmaceuticals: Building Value from the IP Estate

            By: Willy C. Shih and Sen Chai
            The learning objective of this case is to help students recognize the interplay between intellectual property (IP) rights and corporate strategy. We do this by examining what is a fairly atypical circumstance today in which a single firm is able to secure what it... View Details
            Keywords: Patents; Lawsuits and Litigation; Rights; Competitive Strategy; Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; United States
            Citation
            Educators
            Purchase
            Related
            Shih, Willy C., and Sen Chai. "Alnylam Pharmaceuticals: Building Value from the IP Estate." Harvard Business School Case 611-009, September 2010. (Revised July 2013.)
            • October 2014 (Revised July 2016)
            • Supplement

            Gilead: Hepatitis C Access Strategy (B)

            By: V. Kasturi Rangan
            While the "Gilead: Hepatitis-C Access Strategy (A)" case (HBS No. 515-025) poses questions on what the company should do with respect to hard-hit countries like Egypt and India, the (B) case provides the answer. In both cases, the company chose to pursue a proactive... View Details
            Keywords: Emerging Markets; Pharmaceutical Industry; Pharmaceutical Industry
            Citation
            Purchase
            Related
            Rangan, V. Kasturi. "Gilead: Hepatitis C Access Strategy (B)." Harvard Business School Supplement 515-044, October 2014. (Revised July 2016.)
            • June 2020
            • Case

            Breakthroughs at Blueprint Medicines

            By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma
            Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details
            Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts
            Citation
            Educators
            Purchase
            Related
            Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 2020.
            • 16 Aug 2011
            • Working Paper Summaries

            Managing Political Risk in Global Business: Beiersdorf 1914-1990

            Keywords: by Geoffrey Jones & Christina Lubinski; Beauty & Cosmetics

              Stefan H. Thomke

              Stefan Thomke (sthomke@hbs.edu), an authority on the management of innovation, is the William Barclay Harding Professor of Business Administration at Harvard Business School. He has worked with firms on product, process, and... View Details

              Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
              • ←
              • 13
              • 14
              • …
              • 30
              • 31
              • →
              ǁ
              Campus Map
              Harvard Business School
              Soldiers Field
              Boston, MA 02163
              →Map & Directions
              →More Contact Information
              • Make a Gift
              • Site Map
              • Jobs
              • Harvard University
              • Trademarks
              • Policies
              • Accessibility
              • Digital Accessibility
              Copyright © President & Fellows of Harvard College.